Erythropoietin (ESA) Resistance — 50 FAQs

What is ESA resistance?
Failure to achieve or maintain target hemoglobin despite appropriate or escalating ESA doses.
What is the alternative term for ESA resistance?
ESA hyporesponsiveness.
In which population is ESA resistance most common?
CKD patients, especially those on maintenance dialysis.
What is the single most common cause of ESA resistance?
Chronic inflammation.
Which molecule is central to ESA resistance pathophysiology?
Hepcidin.
Which cytokine drives hepcidin production?
Interleukin-6 (IL-6).
What is functional iron deficiency?
Adequate iron stores but impaired iron availability for erythropoiesis.
How does functional iron deficiency present on labs?
Normal or high ferritin with low TSAT.
Why can ferritin be misleading in CKD?
It is an acute-phase reactant and rises with inflammation.
What defines absolute iron deficiency in CKD?
Low ferritin and low TSAT.
What iron route is preferred in ESA-resistant dialysis patients?
Intravenous iron.
Can IV iron be given when ferritin is high?
Yes, if TSAT is low and functional iron deficiency is present.
What is the best marker of ESA hyporesponsiveness severity?
ESA dose-to-hemoglobin ratio.
Why is aggressive ESA dose escalation discouraged?
It increases cardiovascular events, stroke, and hypertension.
Which CKD complication suppresses bone marrow erythropoiesis?
Secondary hyperparathyroidism.
How does high PTH cause ESA resistance?
By causing bone marrow fibrosis and erythroid suppression.
Which nutritional marker predicts poor ESA response?
Low serum albumin.
What does hypoalbuminemia reflect in CKD anemia?
Inflammation and malnutrition.
Which drugs blunt erythropoiesis?
ACE inhibitors and ARBs.
How do ACEi/ARBs impair erythropoiesis?
By inhibiting angiotensin II–mediated erythroid stimulation.
What dialysis factor contributes to ESA resistance?
Inadequate dialysis adequacy (low Kt/V).
Why does poor dialysis worsen anemia?
Uremic toxins suppress marrow response.
Which toxic exposure causes ESA resistance by impairing heme synthesis?
Aluminum.
Which vitamin deficiencies should be excluded?
Vitamin B12 and folate deficiency.
Why must occult blood loss be excluded first?
It is a common, correctable cause of apparent ESA failure.
Which laboratory test best reflects marrow response to ESA?
Reticulocyte count.
What does absent reticulocyte response suggest?
Bone marrow failure or PRCA.
What is pure red cell aplasia (PRCA)?
Antibody-mediated destruction of erythroid precursors due to anti-EPO antibodies.
How does PRCA present clinically?
Sudden severe anemia after prior ESA response.
What is the hallmark lab feature of PRCA?
Severe reticulocytopenia.
Are iron indices abnormal in PRCA?
No, they are typically normal.
What is the management of ESA-induced PRCA?
Permanent discontinuation of ESA and immunosuppression.
Why is ESA resistance a poor prognostic marker?
It reflects systemic inflammation and high cardiovascular risk.
Which outcomes are associated with high ESA doses?
Hypertension, stroke, vascular access thrombosis, mortality.
What hemoglobin target should be avoided in CKD?
Hb ≥13 g/dL.
Is transfusion first-line therapy for ESA resistance?
No, it is reserved for refractory or symptomatic anemia.
What is the role of HIF-PH inhibitors in ESA resistance?
They improve anemia by reducing hepcidin and enhancing iron utilization.
How do HIF-PH inhibitors differ from ESAs?
They produce near-physiologic endogenous EPO levels.
Why are HIF-PH inhibitors effective in inflammatory states?
They bypass hepcidin-mediated iron blockade.
Name examples of HIF-PH inhibitors.
Roxadustat, daprodustat, vadadustat.
What is the first step when Hb does not respond to ESA?
Reassess iron status and inflammation.
Should ESA dose be increased before correcting iron deficiency?
No.
What is the most frequent reversible cause of ESA resistance in dialysis units?
Catheter-related infection.
Which lab pattern suggests inflammation-driven anemia?
High ferritin with low TSAT and elevated CRP.
Why is ESA resistance not just a hematologic issue?
It reflects multisystem disease burden.
What principle guides ESA resistance management?
Treat the underlying cause, not the Hb number.
What is the earliest indicator of ESA effectiveness?
Rise in reticulocyte count.
Which factor shortens RBC lifespan in CKD?
Oxidative stress and uremic milieu.
Is ESA resistance more common in malnourished patients?
Yes.
One-line takeaway for exams?
ESA resistance = inflammation-driven iron restriction with high CV risk—correct the cause, not the dose.

ESA Resistance & HIF-PH Inhibitors — 40 Ultra–High-Difficulty SS MCQs

Q1. In CKD patients with ESA resistance, which pathway primarily explains reduced iron availability despite normal ferritin?

A. IL-6 → hepcidin → ferroportin internalization

B. TNF-α → ferritin degradation

C. IFN-γ → transferrin upregulation

D. Hepcidin → DMT-1 overexpression

IL-6–driven hepcidin blocks ferroportin, trapping iron in macrophages.

Q2. Which trial-level concern limited aggressive ESA dose escalation in CKD?

A. Infection risk

B. Stroke and cardiovascular events

C. Bone marrow failure

D. Iron overload

CHOIR, CREATE, and TREAT showed higher CV risk with higher Hb targets using ESAs.

Q3. ESA hyporesponsiveness index is best expressed as:

A. Ferritin / TSAT

B. CRP / albumin

C. Weekly ESA dose / achieved Hb

D. Hb / reticulocyte count

Dose-to-Hb ratio quantifies biological resistance.

Q4. Which mechanism allows HIF-PH inhibitors to remain effective during inflammation?

A. Suppression of IL-6

B. Increased ferritin synthesis

C. Hepcidin downregulation with improved iron mobilization

D. Direct erythroid progenitor stimulation

HIF stabilization lowers hepcidin and improves iron utilization.

Q5. Compared with ESAs, HIF-PH inhibitors generate EPO levels that are:

A. Supraphysiologic and sustained

B. Near-physiologic and intermittent

C. Suppressed

D. Independent of oxygen sensing

HIF-PH inhibitors stimulate endogenous, physiologic EPO production.

Q6. Functional iron deficiency is best defined as:

A. Low ferritin, low TSAT

B. Normal/high ferritin with low TSAT

C. High ferritin, high TSAT

D. Low ferritin, normal TSAT

Iron is present but unavailable due to hepcidin blockade.

Q7. Which ESA complication correlates most with dose intensity rather than Hb achieved?

A. Iron overload

B. Infection

C. Stroke

D. Hyperkalemia

High ESA doses independently increase stroke risk.

Q8. Sudden loss of ESA response with near-zero reticulocytes suggests:

A. Iron deficiency

B. Occult bleeding

C. Pure red cell aplasia

D. Secondary hyperparathyroidism

Anti-EPO antibody–mediated PRCA is a red-flag diagnosis.

Q9. Which lab pattern most strongly suggests inflammation-driven ESA resistance?

A. Low ferritin, low TSAT

B. High ferritin, low TSAT, high CRP

C. Low albumin, high TSAT

D. High ferritin, high TSAT

Ferritin rises as an acute-phase reactant.

Q10. Secondary hyperparathyroidism causes ESA resistance primarily via:

A. Iron malabsorption

B. Increased RBC destruction

C. Bone marrow fibrosis

D. Reduced EPO receptor density

Excess PTH suppresses erythropoiesis structurally.

Q11. Which dialysis factor most strongly predicts ESA resistance?

A. Dialysate calcium

B. Membrane flux

C. Inadequate Kt/V

D. Dialysis vintage

Uremic toxins impair marrow responsiveness.

Q12. In ESA-resistant CKD, IV iron is justified when:

A. Ferritin <100 ng/mL only

B. TSAT is low despite high ferritin

C. CRP is normal

D. Hb <7 g/dL

Functional iron deficiency responds to IV iron.

Q13. Which medication class suppresses erythropoiesis via angiotensin II inhibition?

A. Beta blockers

B. ACE inhibitors / ARBs

C. Calcium channel blockers

D. MRAs

Angiotensin II stimulates erythroid progenitors.

Q14. Aluminum-related ESA resistance is due to impaired:

A. Iron absorption

B. Heme synthesis

C. EPO receptor binding

D. RBC membrane integrity

Aluminum interferes with iron incorporation into heme.

Q15. Which outcome best explains why ESA resistance is prognostically adverse?

A. Lower Hb alone

B. Dialysis dependence

C. Underlying inflammatory burden

D. Iron deficiency

Inflammation links resistance to mortality.

Q16. HIF-PH inhibitors increase iron availability by increasing:

A. Ferritin synthesis

B. Transferrin saturation directly

C. Ferroportin expression

D. Hepcidin production

Reduced hepcidin allows ferroportin activity.

Q17. Which ESA complication is dose-dependent rather than Hb-dependent?

A. Iron deficiency

B. Hypertension

C. Infection

D. Thrombocytopenia

Rapid erythropoiesis raises BP.

Q18. Best initial step when Hb fails to rise after ESA initiation?

A. Double ESA dose

B. Reassess iron status and inflammation

C. Add transfusion

D. Stop ESA

Always correct reversible causes first.

Q19. Which nutritional marker correlates best with ESA response?

A. BMI

B. Cholesterol

C. Serum albumin

D. Total protein

Albumin reflects inflammation and nutrition.

Q20. Absolute iron deficiency differs from functional iron deficiency by:

A. Low ferritin and low TSAT

B. High ferritin and low TSAT

C. Normal ferritin and normal TSAT

D. High ferritin and high TSAT

True iron store depletion.

Q21. Which ESA-related trial most strongly linked high ESA dose (not achieved Hb) to adverse cardiovascular outcomes?

A. CREATE

B. TREAT

C. CHOIR

D. Normal Hematocrit Trial

CHOIR showed worse outcomes in patients requiring higher ESA doses, independent of hemoglobin achieved.

Q22. ESA hyporesponsiveness is best quantified using:

A. Ferritin/CRP ratio

B. Absolute ESA dose

C. Hemoglobin variability index

D. ESA dose-to-hemoglobin ratio

ESA resistance is best reflected by dose requirement relative to hemoglobin response.

Q23. Which molecular effect of HIF-PH inhibitors directly improves functional iron deficiency?

A. Increased erythroferrone clearance

B. Hepcidin suppression

C. Increased transferrin saturation via IV iron equivalence

D. Reduced ferritin synthesis

HIF-PH inhibitors suppress hepcidin, improving iron mobilization.

Q24. In ESA-resistant CKD patients, which iron profile favors IV iron benefit?

A. Ferritin <50 ng/mL

B. TSAT >30%

C. TSAT <20% with ferritin 300–800 ng/mL

D. Ferritin >1000 ng/mL

Low TSAT with moderate–high ferritin indicates functional iron deficiency.

Q25. Sudden ESA failure with severe anemia and reticulocytopenia suggests:

A. Aluminum toxicity

B. Iron depletion

C. Dialysis inadequacy

D. Pure red cell aplasia

PRCA is characterized by abrupt ESA resistance and absent reticulocyte response.

Q26. Which finding differentiates inflammation-mediated ESA resistance from PRCA?

A. Low hemoglobin

B. Preserved reticulocyte response

C. High ferritin

D. ESA non-response

Reticulocytopenia is characteristic of PRCA, not inflammation.

Q27. Which ESA effect most contributes to hypertension?

A. Increased nitric oxide

B. Reduced plasma volume

C. Increased vascular sensitivity to catecholamines

D. Bradykinin inhibition

ESA increases vascular reactivity, contributing to hypertension.

Q28. Which trial first demonstrated increased stroke risk with higher Hb targets?

A. CHOIR

B. TREAT

C. CREATE

D. PIVOTAL

TREAT showed nearly doubled stroke risk with darbepoetin.

Q29. Which condition most consistently predicts poor ESA response?

A. Diabetes

B. Advanced age

C. Female sex

D. Chronic inflammation

Inflammation via IL-6–hepcidin axis is the dominant driver.

Q30. Which HIF-PH inhibitor property differentiates it from ESAs?

A. Higher peak EPO levels

B. Physiologic EPO production

C. IV administration

D. Iron-independent erythropoiesis

HIF-PH inhibitors induce endogenous, physiologic-range EPO.

Q31. Which mechanistic pathway explains increased thrombosis with high ESA dose independent of Hb level?

A. Increased fibrinogen synthesis

B. Suppressed nitric oxide synthase

C. Platelet activation and endothelial dysfunction

D. Reduced protein C levels

ESA directly increases platelet reactivity and endothelial activation, explaining dose-related thrombosis.

Q32. In TREAT, excess stroke risk with darbepoetin was most strongly associated with:

A. Higher achieved hemoglobin

B. Rapid Hb rise

C. Baseline diabetes

D. ESA exposure itself

Stroke risk correlated with darbepoetin use rather than achieved Hb, reinforcing dose-related toxicity.

Q33. Which HIF-regulated gene most directly enhances iron availability during HIF-PH inhibitor therapy?

A. Ferritin heavy chain

B. Ferroportin

C. DMT1 degradation pathway

D. Hepatic transferrin clearance

HIF activation upregulates ferroportin and improves iron egress from stores.

Q34. Which safety signal requires vigilance with HIF-PH inhibitors due to pleiotropic HIF activation?

A. Hypoglycemia

B. Osteoporosis

C. Tumor progression and pulmonary hypertension

D. Autoimmune hemolysis

Chronic HIF activation raises theoretical concerns of angiogenesis and pulmonary vascular remodeling.

Q35. Which laboratory pattern best predicts ESA non-responsiveness despite adequate iron supplementation?

A. Ferritin <100 ng/mL

B. TSAT <15%

C. High reticulocyte count

D. Elevated CRP with normal ferritin

Inflammation-driven iron restriction predicts ESA failure despite iron repletion.

Q36. Which physiological feature explains lower peak EPO levels with HIF-PH inhibitors versus ESAs?

A. Reduced renal clearance

B. Endogenous transcriptional regulation

C. Hepatic metabolism dominance

D. Lower receptor affinity

HIF-PH inhibitors stimulate endogenous EPO gene transcription within physiologic bounds.

Q37. Which patient phenotype is most likely to benefit from switching ESA to HIF-PH inhibitor?

A. Absolute iron deficiency

B. PRCA

C. Inflammation-driven functional iron deficiency

D. Acute hemorrhage

HIF-PH inhibitors bypass hepcidin-mediated iron blockade.

Q38. Which finding most strongly contraindicates continued ESA dose escalation?

A. Hb plateau at 10 g/dL

B. TSAT 18%

C. Ferritin 600 ng/mL

D. Rising ESA dose with no reticulocyte response

Absent reticulocyte response indicates futility and increased risk.

Q39. Which trial most clearly separated iron strategy from ESA dose in anemia outcomes?

A. CHOIR

B. PIVOTAL

C. TREAT

D. CREATE

PIVOTAL showed proactive IV iron reduced ESA dose and CV events.

Q40. The single best SS-level principle guiding ESA resistance management is:

A. Normalize hemoglobin aggressively

B. Escalate ESA before iron

C. Treat underlying inflammation and iron restriction

D. Prefer transfusion early

ESA resistance reflects systemic disease; correcting the cause improves outcomes.

Erythropoietin Resistance — 50 Ultra-Short One-Liners

ESA resistance is defined by a high ESA dose requirement with poor hemoglobin response.
ESA hyporesponsiveness is most common in CKD and dialysis patients.
Inflammation is the commonest cause of ESA resistance.
IL-6–driven hepcidin excess is central to ESA resistance.
Hepcidin blocks ferroportin and traps iron in macrophages.
Functional iron deficiency means iron is present but unavailable.
Normal or high ferritin does not exclude iron deficiency in CKD.
Low TSAT with normal or high ferritin indicates functional iron deficiency.
Ferritin acts as an acute-phase reactant in CKD.
IV iron can improve ESA response despite high ferritin levels.
ESA dose-to-hemoglobin ratio best quantifies ESA resistance.
High ESA doses predict increased cardiovascular risk.
ESA dose intensity matters more than achieved hemoglobin.
ESA trials showed higher stroke risk with higher Hb targets.
ESA resistance is a poor prognostic marker.
Secondary hyperparathyroidism suppresses marrow erythropoiesis.
High PTH causes bone marrow fibrosis.
Uremic toxins reduce erythroid progenitor responsiveness.
Inadequate dialysis worsens ESA responsiveness.
Hypoalbuminemia reflects inflammation and poor ESA response.
ACE inhibitors and ARBs blunt erythropoiesis.
Angiotensin II physiologically stimulates erythroid progenitors.
Aluminum toxicity impairs heme synthesis.
Absolute iron deficiency shows low ferritin and low TSAT.
Occult blood loss must be excluded before escalating ESA.
Reticulocyte count is the earliest marker of ESA response.
Absent reticulocytosis suggests marrow failure or PRCA.
Pure red cell aplasia presents with sudden ESA failure.
PRCA is caused by anti-erythropoietin antibodies.
In PRCA, iron indices are typically normal.
ESA must be permanently discontinued in PRCA.
Blood transfusion is not first-line therapy for ESA resistance.
Target hemoglobin ≥13 g/dL should be avoided in CKD.
ESA resistance reflects systemic disease rather than isolated anemia.
Catheter-related infection is a frequent reversible cause of ESA resistance.
Chronic inflammation shortens red cell survival.
High ESA doses increase hypertension risk.
Vascular access thrombosis correlates with ESA dose.
HIF-PH inhibitors stabilize hypoxia-inducible factor.
HIF-PH inhibitors reduce hepcidin levels.
HIF-PH inhibitors improve iron mobilization.
HIF-PH inhibitors produce near-physiologic endogenous EPO.
HIF-PH inhibitors are effective in inflammatory anemia.
Roxadustat is an oral HIF-PH inhibitor.
Daprodustat is approved for CKD-related anemia in several regions.
ESA resistance improves more with cause correction than dose escalation.
Iron correction should precede ESA dose increase.
ESA resistance increases mortality independent of hemoglobin level.
Treating inflammation improves ESA responsiveness.
The key principle in ESA resistance is to treat the cause, not the number.

Erythropoietin (ESA) Resistance — 50 FAQs